Charles W. Newton - 09 Feb 2024 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Financial Officer
Signature
/s/ Matthew Lang, as Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
09 Feb 2024
Transactions value $
$0
Form type
4
Filing time
13 Feb 2024, 20:19:16 UTC
Previous filing
20 Nov 2023
Next filing
25 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Award $0 +40K +458.24% $0.00 48.7K 09 Feb 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Stock Option (right to buy) Award $0 +400K $0.00 400K 09 Feb 2024 Common Stock 400K $1.80 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 Includes 2,941 shares acquired on May 18, 2022, 5,787 shares acquired on May 18, 2023 and 1 share acquired on November 17, 2023 under the Issuer's 2021 Employee Stock Purchase Plan.
F3 12.5% of the option shares shall vest on August 9, 2024, with the remaining option shares to vest in equal monthly installments over the following forty-two months.